A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”
This study was published in the June 25, 2014 Nature [I.F >42] by Prof. Wan Y, Krzeszinski and others from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
What we say:
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Natural product therapy for Bone disorders: Parkia javanica Extract inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene.
Parkia javanica Extract, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. Thus, pharmacological formulations encompassing “Parkia javanica Extract or an active compound isolated from it“ can be used to inhibit osteoporosis and bone metastasis.
Idea Proposed/Formulated by: Dr L Boominathan PhD
Citation: Boominathan, L., Natural product therapy for Bone disorders: Parkia-javanica extract inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 8/November/2016, 10.43 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at firstname.lastname@example.org